Luminex Stock Price, News & Analysis (NASDAQ:LMNX)

$20.64 -0.17 (-0.82 %)
(As of 01/19/2018 06:22 AM ET)
Previous Close$20.81
Today's Range$20.52 - $20.80
52-Week Range$17.68 - $22.42
Volume172,600 shs
Average Volume260,650 shs
Market Capitalization$916.77 million
P/E Ratio31.27
Dividend Yield1.17%
Beta0.19

About Luminex (NASDAQ:LMNX)

Luminex logoLuminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company's products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments. The Company has a range of instruments using its xMAP technology, which includes its LUMINEX 100/200 systems offer 100-plex testing; the Company's FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to a range of testing laboratories.

Receive LMNX News and Ratings via Email

Sign-up to receive the latest news and ratings for LMNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:LMNX
CUSIP55027E10
Phone512-219-8020

Debt

Debt-to-Equity RatioN/A
Current Ratio5.96%
Quick Ratio4.61%

Price-To-Earnings

Trailing P/E Ratio31.2732011091077
Forward P/E Ratio42.12
P/E Growth1.99

Sales & Book Value

Annual Sales$270.64 million
Price / Sales3.36
Cash Flow$0.77 per share
Price / Cash26.72
Book Value$9.26 per share
Price / Book2.23

Profitability

Trailing EPS$0.66
Net Income$13.81 million
Net Margins9.52%
Return on Equity6.01%
Return on Assets5.47%

Miscellaneous

Employees914
Outstanding Shares44,050,000

Luminex (NASDAQ:LMNX) Frequently Asked Questions

What is Luminex's stock symbol?

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

How often does Luminex pay dividends? What is the dividend yield for Luminex?

Luminex declared a quarterly dividend on Thursday, December 14th. Investors of record on Friday, December 22nd will be paid a dividend of $0.06 per share on Friday, January 12th. This represents a $0.24 dividend on an annualized basis and a dividend yield of 1.16%. The ex-dividend date is Thursday, December 21st. View Luminex's Dividend History.

How were Luminex's earnings last quarter?

Luminex Co. (NASDAQ:LMNX) released its quarterly earnings results on Monday, October, 30th. The medical instruments supplier reported $0.25 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.19 by $0.06. The medical instruments supplier had revenue of $74.14 million for the quarter, compared to analyst estimates of $74.38 million. Luminex had a net margin of 9.52% and a return on equity of 6.01%. The business's quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.21 earnings per share. View Luminex's Earnings History.

When will Luminex make its next earnings announcement?

Luminex is scheduled to release their next quarterly earnings announcement on Monday, February, 12th 2018. View Earnings Estimates for Luminex.

Where is Luminex's stock going? Where will Luminex's stock price be in 2018?

4 brokerages have issued 1-year price targets for Luminex's stock. Their predictions range from $19.00 to $24.00. On average, they expect Luminex's share price to reach $21.33 in the next year. View Analyst Ratings for Luminex.

What are Wall Street analysts saying about Luminex stock?

Here are some recent quotes from research analysts about Luminex stock:

  • 1. According to Zacks Investment Research, "Luminex’s second quarter saw a strong top line, solid cash flow and soaring profits. The company also beat the Zacks Consensus Estimates on both lines. Luminex’s Assay business is likely to be its key growth driver over the long term. The company also witnessed favorable tidings at the regulatory front in the second quarter. In this regard, the recent CE-IVD mark for the ARIES Norovirus Assay,  the FDA approval of ARIES C. difficile Assay and the reimbursement approval of VERIGENE assay in Japan are noteworthy. Luminex is on the verge of completing its clinical study for Group A Strep and is close to submitting the same for FDA review. On the flipside, the company slashed its third-quarter revenue guidance. Luminex expects revenues at the segment to be impacted by funding challenges related to a multi-year bulk bead contract from a life science customer." (8/24/2017)
  • 2. Piper Jaffray Companies analysts commented, "Luminex announced 4Q16 revenue of $72.3M, in line with preliminary results. Adj. EPS of $0.06 missed the Street's $0.13 estimate. Results in the quarter reflect strong consumables growth, somewhat offset by lighter instrument sales. Management reaffirmed FY17 revenue guidance of $295M-$305M and provided 1Q17 revenue guidance in line with the Street ($73M-$75M; Street: $74.2M). Revenue guidance appears achievable, but we believe shares are fairly valued. We remain Neutral with a $19 price target (was $20) based on ~2.1x FY18 EV/Rev (unchanged) on our revised estimates." (2/7/2017)

Who are some of Luminex's key competitors?

Who are Luminex's key executives?

Luminex's management team includes the folowing people:

  • G. Walter Loewenbaum II, Independent Chairman of the Board (Age 72)
  • Nachum Shamir, President, Chief Executive Officer, Director (Age 63)
  • Harriss T. Currie, Chief Financial Officer, Senior Vice President - Finance, Treasurer (Age 55)
  • Richard W. Rew II, Senior Vice President, General Counsel, Secretary (Age 49)
  • Todd C. Bennett, Senior Vice President - Global Sales and Customer Operations (Age 47)
  • Nancy M. Fairchild, Senior Vice President - Human resources (Age 63)
  • Tadd S. Lazarus M.D., Senior Vice President (Age 60)
  • Randall Myers, Senior Vice President - Global Manufacturing and Quality (Age 55)
  • Robert J. Cresci, Independent Director (Age 73)
  • Stephen L. Eck, Independent Director (Age 65)

Who owns Luminex stock?

Luminex's stock is owned by a number of of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (1.99%), Thomson Horstmann & Bryant Inc. (1.07%), Schwab Charles Investment Management Inc. (0.57%), Benjamin F. Edwards & Company Inc. (0.21%), CWM LLC (0.19%) and Bank of Montreal Can (0.06%). Company insiders that own Luminex stock include G Walter Loewenbaum II, Harriss T Currie, Kevin M Mcnamara, Nachum Shamir and Robert J Cresci. View Institutional Ownership Trends for Luminex.

Who sold Luminex stock? Who is selling Luminex stock?

Luminex's stock was sold by a variety of institutional investors in the last quarter, including CWM LLC and Bank of Montreal Can. Company insiders that have sold Luminex company stock in the last year include G Walter Loewenbaum II and Robert J Cresci. View Insider Buying and Selling for Luminex.

Who bought Luminex stock? Who is buying Luminex stock?

Luminex's stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Thomson Horstmann & Bryant Inc., Schwab Charles Investment Management Inc., Creative Planning and Benjamin F. Edwards & Company Inc.. Company insiders that have bought Luminex stock in the last two years include Harriss T Currie and Nachum Shamir. View Insider Buying and Selling for Luminex.

How do I buy Luminex stock?

Shares of Luminex can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Luminex's stock price today?

One share of Luminex stock can currently be purchased for approximately $20.64.

How big of a company is Luminex?

Luminex has a market capitalization of $916.77 million and generates $270.64 million in revenue each year. The medical instruments supplier earns $13.81 million in net income (profit) each year or $0.66 on an earnings per share basis. Luminex employs 914 workers across the globe.

How can I contact Luminex?

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]


MarketBeat Community Rating for Luminex (LMNX)

Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  111 (Vote Outperform)
Underperform Votes:  245 (Vote Underperform)
Total Votes:  356
MarketBeat's community ratings are surveys of what our community members think about Luminex and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Luminex (NASDAQ:LMNX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.251.751.752.00
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $21.33$19.33$19.33$21.40
Price Target Upside: 6.03% upside5.51% downside5.51% downside2.29% upside

Luminex (NASDAQ:LMNX) Consensus Price Target History

Price Target History for Luminex (NASDAQ:LMNX)

Luminex (NASDAQ:LMNX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/5/2018BTIG ResearchInitiated CoverageBuy -> Buy$24.00HighView Rating Details
10/20/2017Jefferies GroupReiterated RatingHold$21.00N/AView Rating Details
2/7/2017Piper Jaffray CompaniesLower Price TargetNeutral$20.00 -> $19.00N/AView Rating Details
2/7/2017William BlairReiterated RatingMarket PerformN/AView Rating Details
1/18/2017Deutsche BankReiterated RatingSell$18.00N/AView Rating Details
10/12/2016Avondale PartnersInitiated CoverageOutperform$27.00N/AView Rating Details
8/18/2016JPMorgan Chase & Co.UpgradeUnderweight -> Neutral$18.00 -> $22.00N/AView Rating Details
5/3/2016Leerink SwannReiterated RatingHold$22.00N/AView Rating Details
(Data available from 1/19/2016 forward)

Earnings

Luminex (NASDAQ:LMNX) Earnings History and Estimates Chart

Earnings by Quarter for Luminex (NASDAQ:LMNX)

Luminex (NASDAQ LMNX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/12/2018$0.13N/AView Earnings Details
10/30/2017Q3 2017$0.19$0.25$74.38 million$74.14 millionViewN/AView Earnings Details
8/7/2017Q2 2017$0.09$0.20$75.45 million$76.50 millionViewListenView Earnings Details
5/1/2017Q1 2017$0.16$0.28$74.25 million$77.80 millionViewListenView Earnings Details
2/6/2017Q4 2016$0.09$0.11$70.92 million$72.30 millionViewListenView Earnings Details
10/31/2016Q316$0.12$0.21$68.90 million$71.20 millionViewListenView Earnings Details
7/28/2016Q216$0.18$0.33$61.20 million$64.20 millionViewListenView Earnings Details
5/2/2016Q116$0.14$0.29$60.98 million$63.00 millionViewListenView Earnings Details
2/1/2016Q4 2015$0.17$0.48ViewN/AView Earnings Details
11/2/2015Q315$0.11$0.17$57.24 million$60.60 millionViewListenView Earnings Details
8/3/2015Q215$0.12$0.27$57.01 million$58.90 millionViewListenView Earnings Details
5/4/2015Q115$0.12$0.23$56.50 million$57.70 millionViewListenView Earnings Details
2/2/2015Q414$0.12$0.19$58.31 million$58.10 millionViewListenView Earnings Details
10/27/2014Q314$0.10$0.27$56.60 million$56.68 millionViewListenView Earnings Details
7/28/2014Q214$0.10$0.20$55.90 million$55.50 millionViewListenView Earnings Details
4/28/2014Q114$0.12$0.24$55.31 million$56.60 millionViewListenView Earnings Details
2/3/2014Q413$0.07$0.21$56.63 million$55.20 millionViewListenView Earnings Details
11/4/2013Q313$0.11$0.02$54.67 million$50.80 millionViewListenView Earnings Details
7/29/2013Q2 2013$0.10$0.17$54.16 million$54.30 millionViewListenView Earnings Details
4/29/2013Q1 2013$0.08$0.19$51.94 million$53.20 millionViewListenView Earnings Details
2/4/2013Q4 2012$0.08$0.12$54.09 million$55.53 millionViewListenView Earnings Details
10/29/2012Q312$0.06$0.04$51.26 million$50.00 millionViewN/AView Earnings Details
7/30/2012$0.08$0.07ViewN/AView Earnings Details
4/30/2012$0.09$0.08ViewN/AView Earnings Details
2/6/2012$0.07$0.11ViewN/AView Earnings Details
11/1/2011$0.05$0.05ViewN/AView Earnings Details
8/8/2011$0.06$0.11ViewN/AView Earnings Details
5/9/2011$0.06$0.11ViewN/AView Earnings Details
2/7/2011$0.05$0.07ViewN/AView Earnings Details
11/4/2010Q3 2010$0.04($0.02)ViewN/AView Earnings Details
8/5/2010Q2 2010$0.05$0.02ViewN/AView Earnings Details
5/6/2010Q1 2010$0.05$0.05ViewN/AView Earnings Details
2/4/2010Q4 2009$0.07$0.12ViewN/AView Earnings Details
11/4/2009Q3 2009$0.07($0.02)ViewN/AView Earnings Details
8/6/2009Q2 2009$0.07$0.03ViewN/AView Earnings Details
5/7/2009Q1 2009$0.06$0.04ViewN/AView Earnings Details
2/5/2009Q4 2008$0.06$0.05ViewN/AView Earnings Details
11/6/2008Q3 2008$0.01$0.08ViewN/AView Earnings Details
8/7/2008Q2 2008($0.02)($0.03)ViewN/AView Earnings Details
5/8/2008Q1 2008($0.03)($0.03)ViewN/AView Earnings Details
2/7/2008Q4 2007($0.04)$0.10ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Luminex (NASDAQ:LMNX) Earnings Estimates

2018 EPS Consensus Estimate: $0.62
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.17$0.17$0.17
Q2 20181$0.15$0.15$0.15
Q3 20181$0.14$0.14$0.14
Q4 20181$0.16$0.16$0.16
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Luminex (NASDAQ:LMNX) Dividend Information

Most Recent Dividend:1/12/2018
Annual Dividend:$0.24
Dividend Yield:1.16%
Payout Ratio:36.36% (Trailing 12 Months of Earnings)
48.98% (Based on This Year's Estimates)
36.92% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Luminex (NASDAQ:LMNX)

Luminex (NASDAQ:LMNX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/14/2017quarterly$0.061.18%12/21/201712/22/20171/12/2018
9/12/2017Quarterly$0.061.2%9/21/20179/22/201710/13/2017
5/25/2017quarterly$0.061.18%6/21/20176/23/20177/14/2017
2/22/2017special$0.063/22/20173/24/20174/14/2017
(Data available from 1/1/2013 forward)

Insider Trades

Luminex (NASDAQ LMNX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.90%
Institutional Ownership Percentage: 79.16%
Insider Trades by Quarter for Luminex (NASDAQ:LMNX)
Institutional Ownership by Quarter for Luminex (NASDAQ:LMNX)

Luminex (NASDAQ LMNX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/18/2017G Walter Loewenbaum IIDirectorSell10,503$20.61$216,466.83564,217View SEC Filing  
12/14/2017G Walter Loewenbaum IIDirectorSell31,739$20.49$650,332.11574,720View SEC Filing  
12/12/2017G Walter Loewenbaum IIDirectorSell39,456$20.40$804,902.40651,736View SEC Filing  
11/16/2017G Walter Loewenbaum IIDirectorSell50,000$21.79$1,089,500.00View SEC Filing  
8/23/2017Robert J CresciDirectorSell19,631$18.98$372,596.38260,358View SEC Filing  
5/30/2017G Walter Loewenbaum IIDirectorSell25,000$20.07$501,750.00713,896View SEC Filing  
5/23/2017G Walter Loewenbaum IIDirectorSell25,000$20.23$505,750.00738,896View SEC Filing  
5/18/2017G Walter Loewenbaum IIDirectorSell25,000$20.80$520,000.00View SEC Filing  
1/26/2017G Walter Loewenbaum IIDirectorSell20,000$19.75$395,000.00766,240View SEC Filing  
1/19/2017G Walter Loewenbaum IIDirectorSell20,000$19.82$396,400.00766,240View SEC Filing  
1/12/2017G Walter Loewenbaum IIDirectorSell20,000$20.43$408,600.00766,240View SEC Filing  
1/5/2017G Walter Loewenbaum IIDirectorSell20,000$20.32$406,400.00766,240View SEC Filing  
12/29/2016G Walter Loewenbaum IIDirectorSell20,000$20.27$405,400.00766,240View SEC Filing  
11/28/2016G Walter Loewenbaum IIDirectorSell50,000$20.57$1,028,500.00749,414View SEC Filing  
11/15/2016Kevin M McnamaraDirectorSell12,000$21.03$252,360.0067,274View SEC Filing  
11/3/2016Harriss T. CurrieSVPBuy4,100$18.20$74,620.00View SEC Filing  
11/3/2016Nachum ShamirCEOBuy6,000$18.22$109,320.00105,010View SEC Filing  
1/4/2016G Walter Loewenbaum IIDirectorSell41,056$20.53$842,879.68788,583View SEC Filing  
12/31/2015G Walter Loewenbaum IIDirectorSell18,944$21.65$410,137.60829,639View SEC Filing  
12/16/2015Russell W. BradleyCMOSell6,514$22.75$148,193.50104,067View SEC Filing  
5/28/2015Nachum ShamirCEOBuy6,000$16.73$100,380.00View SEC Filing  
5/27/2015G Walter Loewenbaum IIDirectorBuy38,966$16.71$651,121.86View SEC Filing  
2/5/2015Fred C Goad JrDirectorSell25,000$15.46$386,500.00View SEC Filing  
10/8/2014Russell W BradleySVPSell5,000$20.50$102,500.00View SEC Filing  
5/15/2014Patrick BalthropCEOSell70,000$17.69$1,238,300.00486,367View SEC Filing  
5/12/2014Kevin McnamaraDirectorSell5,000$17.95$89,750.0060,614View SEC Filing  
5/9/2014Jim KeverDirectorSell5,000$17.52$87,600.00187,745View SEC Filing  
5/7/2014Patrick BalthropCEOSell32,575$17.63$574,297.25556,367View SEC Filing  
5/6/2014Patrick BalthropCEOSell60,000$18.28$1,096,800.00545,833View SEC Filing  
5/2/2014Fred Goad, Jr.DirectorSell50,000$18.86$943,000.00312,745View SEC Filing  
5/2/2014Patrick BalthropCEOSell55,000$19.05$1,047,750.00524,937View SEC Filing  
5/1/2014David ReiterSVPSell15,000$19.09$286,350.0060,400View SEC Filing  
5/1/2014Harriss CurrieCFOSell11,000$19.08$209,880.00186,576View SEC Filing  
9/23/2013Harriss CurrieCFOSell30,000$19.88$596,400.00167,748View SEC Filing  
9/17/2013Harriss CurrieCFOSell30,000$19.87$596,100.00167,748View SEC Filing  
9/13/2013Michael PintekSVPSell3,000$20.00$60,000.0054,392View SEC Filing  
8/30/2013G Walter Loewenbaum IIDirectorBuy6,034$20.62$124,421.08864,662View SEC Filing  
8/28/2013G Walter Loewenbaum IIDirectorBuy20,000$20.76$415,200.00858,628View SEC Filing  
8/16/2013Timothy DehneVPSell32,297$20.66$667,256.0220,441View SEC Filing  
8/15/2013G Walter Loewenbaum IIDirectorBuy10,000$20.82$208,200.00838,628View SEC Filing  
8/14/2013Timothy DehneVPSell1,793$21.21$38,029.5320,441View SEC Filing  
8/9/2013G Walter Loewenbaum IIDirectorBuy4,600$21.17$97,382.00828,628View SEC Filing  
8/2/2013G Walter Loewenbaum IIDirectorBuy27,000$20.01$540,270.00823,628View SEC Filing  
8/2/2013Patrick J BalthropCEOSell68,048$20.01$1,361,640.48View SEC Filing  
8/1/2013David S ReiterSVPSell15,000$20.00$300,000.00View SEC Filing  
8/1/2013Thomas W EricksonDirectorSell20,000$20.00$400,000.00View SEC Filing  
5/24/2013Fred C Goad JrDirectorBuy11,250$18.25$205,312.50View SEC Filing  
5/17/2013G Walter Loewenbaum IIDirectorBuy13,000$18.37$238,810.00791,628View SEC Filing  
5/16/2013Fred C Goad JrDirectorBuy8,000$18.18$145,440.00View SEC Filing  
5/15/2013G Walter Loewenbaum IIDirectorBuy39,500$18.32$723,640.00View SEC Filing  
5/10/2013David S ReiterSVPSell10,000$18.26$182,600.00View SEC Filing  
5/10/2013G Walter Loewenbaum IIDirectorBuy19,000$18.13$344,470.00View SEC Filing  
5/9/2013G Walter Loewenbaum IIDirectorBuy28,300$17.21$487,043.00View SEC Filing  
5/7/2013G Walter Loewenbaum IIDirectorBuy64,935$17.17$1,114,933.95View SEC Filing  
5/3/2013G Walter Loewenbaum IIDirectorBuy24,765$17.02$421,500.30View SEC Filing  
9/4/2012David S ReiterVPSell10,000$20.00$200,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Luminex (NASDAQ LMNX) News Headlines

Source:
DateHeadline
Luminex Announces Preliminary Revenue for the Fourth Quarter and Full Year 2017; Company to Present at 36th Annual J.P. Morgan Healthcare ConferenceLuminex Announces Preliminary Revenue for the Fourth Quarter and Full Year 2017; Company to Present at 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 7 at 5:09 PM
Luminex (LMNX) Research Coverage Started at BTIG ResearchLuminex (LMNX) Research Coverage Started at BTIG Research
www.americanbankingnews.com - January 5 at 8:54 AM
Luminex Co. (LMNX) Given Average Rating of "Hold" by BrokeragesLuminex Co. (LMNX) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - January 1 at 11:50 AM
BidaskClub Downgrades Luminex (LMNX) to Strong SellBidaskClub Downgrades Luminex (LMNX) to Strong Sell
www.americanbankingnews.com - December 27 at 7:26 PM
$76.74 Million in Sales Expected for Luminex Co. (LMNX) This Quarter$76.74 Million in Sales Expected for Luminex Co. (LMNX) This Quarter
www.americanbankingnews.com - December 27 at 5:08 PM
Abbott Rides High on FDA Approvals & Buyouts Amid HeadwindsAbbott Rides High on FDA Approvals & Buyouts Amid Headwinds
finance.yahoo.com - December 22 at 10:12 AM
Luminex Co. (LMNX) Director Sells $216,466.83 in StockLuminex Co. (LMNX) Director Sells $216,466.83 in Stock
www.americanbankingnews.com - December 21 at 2:20 PM
Luminex (LMNX) versus Hansen Medical (HNSN) Financial ReviewLuminex (LMNX) versus Hansen Medical (HNSN) Financial Review
www.americanbankingnews.com - December 21 at 1:12 PM
PerkinElmer (PKI) Closes EUROIMMUN Acquisition for $1.3BPerkinElmer (PKI) Closes EUROIMMUN Acquisition for $1.3B
finance.yahoo.com - December 20 at 10:08 AM
Why Luminex Corporation (NASDAQ:LMNX) Delivered An Inferior ROE Compared To The IndustryWhy Luminex Corporation (NASDAQ:LMNX) Delivered An Inferior ROE Compared To The Industry
finance.yahoo.com - December 17 at 10:03 AM
Insider Selling: Luminex Co. (LMNX) Director Sells 31,739 Shares of StockInsider Selling: Luminex Co. (LMNX) Director Sells 31,739 Shares of Stock
www.americanbankingnews.com - December 15 at 6:06 PM
Luminex (LMNX) vs. Its Competitors Financial ComparisonLuminex (LMNX) vs. Its Competitors Financial Comparison
www.americanbankingnews.com - December 15 at 1:34 PM
Here's Why You Should Invest in Illumina (ILMN) Stock NowHere's Why You Should Invest in Illumina (ILMN) Stock Now
finance.yahoo.com - December 15 at 10:31 AM
Luminex Co. (LMNX) Announces $0.06 Quarterly DividendLuminex Co. (LMNX) Announces $0.06 Quarterly Dividend
www.americanbankingnews.com - December 14 at 5:56 PM
Luminex Co. (LMNX) Director Sells $804,902.40 in StockLuminex Co. (LMNX) Director Sells $804,902.40 in Stock
www.americanbankingnews.com - December 13 at 5:46 PM
Luminex Corporation Declares Fourth Quarter Cash DividendLuminex Corporation Declares Fourth Quarter Cash Dividend
finance.yahoo.com - December 13 at 4:59 PM
Luna Innovations (LUNA) & Luminex (LMNX) Head-To-Head AnalysisLuna Innovations (LUNA) & Luminex (LMNX) Head-To-Head Analysis
www.americanbankingnews.com - December 12 at 1:38 AM
BidaskClub Downgrades Luminex (LMNX) to SellBidaskClub Downgrades Luminex (LMNX) to Sell
www.americanbankingnews.com - December 10 at 2:30 PM
Zacks: Brokerages Expect Luminex Co. (LMNX) Will Announce Quarterly Sales of $76.74 MillionZacks: Brokerages Expect Luminex Co. (LMNX) Will Announce Quarterly Sales of $76.74 Million
www.americanbankingnews.com - December 9 at 3:56 PM
Luminex Co. (LMNX) Receives Consensus Recommendation of "Hold" from AnalystsLuminex Co. (LMNX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 7 at 11:50 AM
Luminex Corp. – Value Analysis (NASDAQ:LMNX) : December 6, 2017Luminex Corp. – Value Analysis (NASDAQ:LMNX) : December 6, 2017
finance.yahoo.com - December 6 at 4:51 PM
Luminex Corp. breached its 50 day moving average in a Bearish Manner : LMNX-US : December 5, 2017Luminex Corp. breached its 50 day moving average in a Bearish Manner : LMNX-US : December 5, 2017
finance.yahoo.com - December 5 at 11:47 AM
Comparing Luminex (LMNX) & Its PeersComparing Luminex (LMNX) & Its Peers
www.americanbankingnews.com - December 4 at 3:26 AM
Here's Why You Should Invest in Baxter (BAX) Stock Right NowHere's Why You Should Invest in Baxter (BAX) Stock Right Now
finance.yahoo.com - November 30 at 10:38 AM
Patterson Companies Dental Business Dull, Competition RifePatterson Companies Dental Business Dull, Competition Rife
finance.yahoo.com - November 28 at 10:00 AM
Head to Head Contrast: Luminex (LMNX) & Its CompetitorsHead to Head Contrast: Luminex (LMNX) & Its Competitors
www.americanbankingnews.com - November 26 at 11:06 PM
Luminex (LMNX) at 52-Week High: Whats Driving the Stock?Luminex (LMNX) at 52-Week High: What's Driving the Stock?
www.zacks.com - November 24 at 9:44 AM
Five Scorching Hot Strong Buy StocksFive Scorching Hot Strong Buy Stocks
finance.yahoo.com - November 22 at 2:08 AM
$76.74 Million in Sales Expected for Luminex Corporation (LMNX) This Quarter$76.74 Million in Sales Expected for Luminex Corporation (LMNX) This Quarter
www.americanbankingnews.com - November 21 at 12:04 PM
Luminex Corporation (LMNX) Expected to Announce Earnings of $0.11 Per ShareLuminex Corporation (LMNX) Expected to Announce Earnings of $0.11 Per Share
www.americanbankingnews.com - November 19 at 11:28 AM
Critical Review: Luminex Corporation (LMNX) and Its CompetitorsCritical Review: Luminex Corporation (LMNX) and Its Competitors
www.americanbankingnews.com - November 18 at 5:12 AM
G Walter Loewenbaum II Sells 50,000 Shares of Luminex Corporation (LMNX) StockG Walter Loewenbaum II Sells 50,000 Shares of Luminex Corporation (LMNX) Stock
www.americanbankingnews.com - November 17 at 1:50 PM
Myriad Genetics' Latest Alliance to Boost GeneSight ReachMyriad Genetics' Latest Alliance to Boost GeneSight Reach
finance.yahoo.com - November 17 at 1:40 PM
Can Luminex Light The Way?Can Luminex Light The Way?
seekingalpha.com - November 15 at 5:08 AM
Weight Watchers (WTW) to Issue $500M Senior Notes Due 2025Weight Watchers (WTW) to Issue $500M Senior Notes Due 2025
finance.yahoo.com - November 15 at 5:08 AM
Luminex Corporation To Present At The 29th Annual Piper Jaffray Healthcare ConferenceLuminex Corporation To Present At The 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 15 at 5:08 AM
BioTelemetry (BEAT) Q3 Earnings Miss, Revenues Meet EstimatesBioTelemetry (BEAT) Q3 Earnings Miss, Revenues Meet Estimates
finance.yahoo.com - November 13 at 3:01 PM
Bio-Rad (BIO) Beats Earnings and Revenue Estimates in Q3Bio-Rad (BIO) Beats Earnings and Revenue Estimates in Q3
finance.yahoo.com - November 13 at 3:01 PM
ETFs with exposure to Luminex Corp. : November 13, 2017ETFs with exposure to Luminex Corp. : November 13, 2017
finance.yahoo.com - November 13 at 3:01 PM
Medtronic Preliminary Sales Dip Y/Y, Hurricane Blow LessensMedtronic Preliminary Sales Dip Y/Y, Hurricane Blow Lessens
finance.yahoo.com - November 13 at 3:01 PM
Luminex Corporation (LMNX) Forecasted to Post FY2017 Earnings of $0.49 Per ShareLuminex Corporation (LMNX) Forecasted to Post FY2017 Earnings of $0.49 Per Share
www.americanbankingnews.com - November 13 at 2:58 AM
Luminex Corporation (LMNX) Given Consensus Rating of "Hold" by BrokeragesLuminex Corporation (LMNX) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 12 at 2:16 PM
Myriad Genetics (MYGN) Beats on Q1 Earnings & RevenuesMyriad Genetics (MYGN) Beats on Q1 Earnings & Revenues
finance.yahoo.com - November 8 at 2:17 PM
Penumbra (PEN) Posts Earnings, Revenues Top Estimates in Q3Penumbra (PEN) Posts Earnings, Revenues Top Estimates in Q3
finance.yahoo.com - November 8 at 2:17 PM
VWR Q3 Earnings Top, Sell-Off to Avantor Approaching ClosureVWR Q3 Earnings Top, Sell-Off to Avantor Approaching Closure
finance.yahoo.com - November 8 at 2:17 PM
STERIS (STE) Q2 Earnings Miss & Revenues Beat, Margins UpSTERIS (STE) Q2 Earnings Miss & Revenues Beat, Margins Up
finance.yahoo.com - November 3 at 8:04 PM
Omnicell's Higher Investments Drive Costs, Competition RifeOmnicell's Higher Investments Drive Costs, Competition Rife
finance.yahoo.com - November 3 at 8:04 PM
DexCom (DXCM) Q3 Loss Narrower Than Expected, Revenues MeetDexCom (DXCM) Q3 Loss Narrower Than Expected, Revenues Meet
finance.yahoo.com - November 3 at 8:04 PM
First Week of January 2018 Options Trading For LuminexFirst Week of January 2018 Options Trading For Luminex
www.nasdaq.com - November 3 at 3:03 PM
PerkinElmer (PKI) Beats Q3 Earnings, Updates '17 GuidancePerkinElmer (PKI) Beats Q3 Earnings, Updates '17 Guidance
finance.yahoo.com - November 3 at 3:03 PM

SEC Filings

Luminex (NASDAQ:LMNX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Luminex (NASDAQ:LMNX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Luminex (NASDAQ LMNX) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.